WO2004026300A1 - COMBINATIONS OF ATORVASTATIN AND α1, ADRENERGIC RECEPTOR ANTAGONISTS - Google Patents
COMBINATIONS OF ATORVASTATIN AND α1, ADRENERGIC RECEPTOR ANTAGONISTS Download PDFInfo
- Publication number
- WO2004026300A1 WO2004026300A1 PCT/IB2003/003940 IB0303940W WO2004026300A1 WO 2004026300 A1 WO2004026300 A1 WO 2004026300A1 IB 0303940 W IB0303940 W IB 0303940W WO 2004026300 A1 WO2004026300 A1 WO 2004026300A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- acceptable derivative
- bph
- atorvastatin
- treatment
- Prior art date
Links
- KSKDGPDHMFKFKX-UHFFFAOYSA-N COc(cc1C2CC2)cc(F)c1C#N Chemical compound COc(cc1C2CC2)cc(F)c1C#N KSKDGPDHMFKFKX-UHFFFAOYSA-N 0.000 description 1
- SXHZMFYMBCKFSF-UHFFFAOYSA-N COc(cc1C2CC2)cc(N)c1C#N Chemical compound COc(cc1C2CC2)cc(N)c1C#N SXHZMFYMBCKFSF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
Definitions
- This invention relates to combinations of atorvastatin and ⁇ adrenergic receptor antagonists, the use of such combinations in the treatment of benign prostatic hyperplasia (BPH), methods of treating BPH using such combinations and medicaments containing such combinations.
- BPH benign prostatic hyperplasia
- BPH is a chronically progressive disease that can lead to complications such as acute urinary retention, recurrent urinary tract infections, bladder stones and renal dysfunction.
- LUTS lower urinary tract symptoms
- BPH leads to an increase in prostate volume, creating urethral and bladder outflow obstruction as well as secondary changes in bladder function.
- the effects of this are manifested by both storage (irritative) and voiding (obstructive) symptoms, giving rise to nocturia, urinary urgency and poor urinary flow.
- Atorvastatin calcium disclosed in U.S. Patent No. 5,273,995, is currently sold as Lipitor ® , and is [R-(R*, R*)]-2-(4-fluorophenyl)- ⁇ , ⁇ -dihydroxy-5-(1- methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1 H-pyrrole-1 -heptanoic acid hemi calcium salt, represented by formula I below:
- Italian Patent Application No. 048658 describes the use of HMG-CoA reductase inhibitors for the treatment of BPH.
- JP56115717 discloses the use of two HMG-CoA reductase inhibitors (monacholin K and ML-236B) for treating prostatomegaly.
- US2002/0004521 describes the use of atorvastatin for the treatment of BPH.
- Combinations of 5 ⁇ -reductase inhibitors with ⁇ -adrenergic receptor antagonists are described for use in the treatment of BPH in US Patent No. 5,753,641.
- WO 99/11260 concerns the combination of atorvastatin with an antihypertensive agent, which may comprise an ⁇ -adrenergic receptor antagonist. Such combinations are useful in the treatment of angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and for the treatment of subjects presenting with symptoms of cardiac risk.
- This invention provides the use of a combination of (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) an ⁇ adrenergic receptor antagonist or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the treatment of BPH.
- Pharmaceutically acceptable derivatives include pharmaceutically acceptable salts and pharmaceutically acceptable solvates.
- the combinations of the invention may have the advantage that, due to a synergistic interaction between the active ingredients, they are more potent, have a longer duration of action, more effectively reduce disease progression and, therefore, the requirement for surgical intervention, have a broader range of activity, are more stable, have fewer side effects or are more selective (in particular they may have beneficial effects in BPH without causing undesirable cardiovascular effects) or have other more useful properties than the prior art.
- ⁇ -i-Adrenergic receptor antagonists useful for (B) include, but are not limited to, terazosin (US Patent No. 4,026,894), doxazosin (US Patent No. 4,188,390), prazosin (US Patent No. 3,511 ,836), bunazosin (US Patent No. 3,920,636), alfuzosin (US Patent No.
- PCT/IB03/00998 in particular 5-cyclopropyl-7-methoxy-2-(2-morpholin-4- ylmethyl-7,8-dihydro[1 ,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone (example 11), and 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1 , 2,3,4- tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (International Patent Application Publication No. WO 98/30560, example 19); and pharmaceutically acceptable derivatives thereof.
- Preferred ⁇ -adrenergic receptor antagonists are doxazosin, 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1 ,6]- naphthyridin-6(5H)-yl)-4(3H)-quinazolinone and 4-Amino-6,7-dimethoxy-2-(5- methanesulfonamido-1 ,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline and pharmaceutically acceptable derivatives thereof.
- the mesylate salt of 4- Amino-6,7-dimethoxy-2-(5-methanesulfonamido-1 ,2,3,4-tetrahydroisoquinol-2- yl)-5-(2-pyridyl)quinazoline is of particular interest (see WO 01/64672).
- One embodiment of the invention comprises a pharmaceutical composition
- a pharmaceutical composition comprising (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) doxazosin or a pharmaceutically acceptable derivative thereof.
- An alternative embodiment comprises a pharmaceutical composition
- a pharmaceutical composition comprising (A) atorvastatin or a pharmaceutically acceptable salt thereof and (B) 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl-7,8-dihydro[1 ,6]- naphthyridin-6(5H)-yl)-4(3H)-quinazolinone or a pharmaceutically acceptable salt thereof.
- a further embodiment comprises a pharmaceutical composition comprising (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 4- amino-6,7-dimethoxy-2-(5-methanesulfonamido-1 ,2,3,4-tetrahydroisoquinol-2- yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable derivative thereof.
- An additional embodiment comprises a pharmaceutical composition comprising
- a medicament containing, separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1 ,2,3,4- tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline or a pharmaceutically acceptable derivative thereof, for simultaneous, sequential or separate administration in the treatment of BPH.
- a medicament containing, separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) 5-cyclopropyl-7-methoxy-2-(2-morpholin-4-ylmethyl- 7,8-dihydro[1 ,6]-naphthyridin-6(5H)-yl)-4(3H)-quinazolinone or a pharmaceutically acceptable salt thereof, for simultaneous, sequential or separate administration in the treatment of BPH.
- a further embodiment comprises a medicament containing separately or together, (A) atorvastatin or a pharmaceutically acceptable derivative thereof and (B) doxazosin or a pharmaceutically acceptable salt thereof, for simultaneous, sequential or separate administration in the treatment of BPH.
- composition comprising a mixture of effective amounts of (A) as hereinbefore defined and
- compositions of the present invention are present in an amount ranging from 10 mg to 80 mg per dose, and (B) is present in an amount ranging from 0.1 mg to 20 mg per dose.
- the physician in any event will determine the actual dosage which will be most suitable for any individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited and such are within the scope of this invention.
- compositions of the present invention can be administered alone but will generally be administered in a mixture with a suitable pharmaceutical excipient, diluent or carried selected with regard to the intended route of administration and standard pharmaceutical practice.
- the pharmaceutical compositions can be administered orally, buccally or sublingually in the form of tablets, capsules, multi-particulates, gels, films, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
- the pharmaceutical compositions may also be administered as fast-dispersing or fast-dissolving dosage forms or in the form of a high energy dispersion or as coated particles. Suitable formulations of the pharmaceutical compositions may be in coated or uncoated form.
- Solid pharmaceutical compositions may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine and starch (preferably corn, potato or tapioca starch), disintegrants such as sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
- excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine and starch (preferably corn, potato or tapioca starch), disintegrants such as sodium starch glycollate, croscarmellose sodium and certain complex silicates, and
- compositions may also be administered in the form of a suppository for rectal administration.
- a suitable non-irritating excipients which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- Such materials are cocoa butter and polyethylene glycols.
- the combination of this invention may also be administered in a controlled- release dosage formulation such as a slow release or a fast release formulation.
- Such controlled release formulations of the combination of this invention may be prepared according to methods well known to those skilled in the art.
- compositions according to the invention may contain 0.1 %-95% of the compounds of this invention, preferably 1%-70%.
- Still further provided by the present invention is a method of treating BPH comprising administering to a subject in need of such treatment amounts of (A) as hereinbefore described and (B) as hereinbefore described which are together effective.
- Effective amounts as used herein is an amount of (A) and (B) that will elicit the biological or medical response being sought.
- the daily dose of (A) and (B) employed in the method of treatment is similar to the doses described for use in the pharmaceutical compositions hereinbefore described.
- (A) and (B) can be administered together combined in a single dosage form, or they can be administered separately, essentially concurrently, each in its own dosage form but as part of the same therapeutic treatment program, and it is envisaged that (A) and (B) may be separately administered, at different times and by different routes.
- This study is designed to investigate the effects of atorvastatin at 1 , 10 and 30 mg/kg, and concomitant treatment with 0.1 mg/kg of doxazosin on bladder function (as assessed by cystometry i.e. the flow of urine through the bladder/urethra) and gross prostate morphology (prostate weight, stromal/epithelial volume) of spontaneous hypertensive rats (SHR).
- SHR's have increased prostate size (increased stromal and epithelial growth), and bladder hyperactivity relative to their normotensive Wistar-Kyoto (WKY) counterparts.
- WKY Wistar-Kyoto
- the animals were group housed under 12:12 hour light:dark cycle. They were offered a standard rat diet and water ad libitum.
- the SHR and WKY animals were administered orally their respective treatments for a period of 60 days.
- Micturition parameters (frequency, volume void and total volume over a 2 hour period) were assessed on a sub-group of animals on days 0, 25 and 50 of the study.
- urethane 1.2 g/kg, i.p.
- Depth of anaesthesia was assessed by the stability of blood pressure and heart rate, and by an absence of hind limb withdrawal in response to paw pinch.
- Supplementary doses of urethane (0.1 g kg-1 , i.v.) were given where necessary.
- the trachea was intubated to maintain a patent airway.
- the left jugular vein was cannulated for drug administration, and the left common carotid artery was cannulated with a heparinised cannula (20 units/ml heparin in 0.9% w/v saline) for the measurement of arterial blood pressure and for sampling arterial blood for blood gas analysis.
- Blood pressure was measured using a pressure transducer (Gould Statham P23Db), and the heart rate (HR) derived electronically on-line from the blood pressure using PoneMah (Linton Pty Ltd UK). Body temperature was monitored with a rectal temperature probe and maintained between 36 - 38°C using a homeothermic blanket system (Harvard, UK).
- the animals either spontaneously breathed air or were artificially ventilated, and blood gases were maintained between 90 - 130 mmHg Po2, 40 - 50 mmHg PCo2 and pH 7.3 - 7.4. Adjustments of the supplemented oxygen levels (spontaneously breathing animals) and respiratory pump rate and volume (artificially ventilated animals) were made as necessary to maintain blood gas and pH balance.
- the urinary bladder was exposed by a midline abdominal incision. A cut was made in the bladder dome and double lumen cannula (0.52 mm internal and 1.2 mm external diameter) was inserted into the bladder, one of which was connected to a pressure transducer (Gould Statham P23Db) to record intravesical bladder pressure, and the other connected to a syringe pump for the infusion of saline (0.9% w/v) to evoke the micturition reflex.
- the rate (0.046 ml/min) of infusion of saline into the bladder was chosen to simulate the maximal hourly diuresis rate (Klevmark, 1974).
- a microsphere technique was employed to assess the effects of treatment on prostate and bladder blood flow (see Das et al, 2002). Briefly, 2 million Nuflow fluorescent red microspheres (IMT; 15 ⁇ m diameter suspended in 0.4 mL of 0.9% saline and 0.01 % Tween-80) were injected via the carotid catheter. Blood samples were collected prior to, during and following the infusion of microspheres. Five minutes after the infusion the rats were euthanised and the bladder, urethra and prostate collected and blood flow determined. Any change in prostate size alters bladder blood flow and improves bladder function.
- IMT Nuflow fluorescent red microspheres
- the prostate of the rats was collected, weighed, stored in 10% formalin pending gross morphological examination of the stroma and epithelial thickness.
- reaction mixture was then added slowly to an ice-cold solution of amino-2-methylpropanol (3.56g, 40mmol), in dichloromethane (50mL). After stirring at room temperature for 1 hour, the reaction mixture was washed with water (75mL), 0.2N hydrochloric acid (50mL), dried (MgSO 4 ) and concentrated under reduced pressure to give the title compound as a white solid (2.77g, 96%).
- the compound from preparation 10 (9.51 g, 31 mmol) was suspended in acetonitrile (45mL) and anisole (45mL). Phosphorous oxybromide (44.8g, 156mmol) was added portionwise and the mixture heated for 1 hour at 120°C. The reaction was allowed to cool to room temperature and then poured onto ice (400g). Dichloromethane (400mL) was added and the mixture was then neutralised with saturated sodium carbonate solution (450mL). The organic layer was collected and the aqueous layer extracted with dichloromethane (500mL). The combined organic solutions were dried (MgSO ) and concentrated under reduced pressure.
- Tri-te/f-butylphosphine (3.0 g, 15.28 mmol) was added to a solution of tris(dibenzylideneacetone)dipalladium (4.2 g, 4.63 mmol) in 1 ,4-dioxane (45 ml), under argon, and the solution stirred for 30 minutes at room temperature.
- the pH of the mixture was adjusted to 8 using sodium bicarbonate, the phases separated, and the aqueous layer re-extracted with ethyl acetate (2x100 ml).
- the combined organic solutions were dried over magnesium sulphate and evaporated under reduced pressure.
- the crude product was pre-adsorbed onto silica gel, and purified by column chromatography using an elution gradient of cyclohexane: ethyl acetate (84:16 to 66:34) to afford the title compound as an orange-red oil, (15.8 g).
- Osmium tetroxide (8.3 ml, 2.5%wt.in te/f-butanol) was added dropwise to a mixture of the compound from preparation 13 (11.3 g, 32.2 mmol), N- methylmorpholine N-oxide (4.15 g, 35.4 mmol) in water (80 ml) and acetone (160 ml), and the reaction was stirred at room temperature for 72 hours. The mixture was concentrated under reduced pressure, and the residue azeotroped with acetone. The crude product was purified by column chromatography on silica gel using an elution gradient of cyclohexane: ethyl acetate (80:25 to 25:75), to afford the title compound as a gum (7.2 g).
- a solution of sodium periodate (4.38 g, 20.5 mmol) in water (38 ml) was added dropwise to a solution of the diol from preparation 14 (7.2 g, 18.7 mmol) in acetonitrile (200 ml), and the reaction was stirred at room temperature for 2 hours.
- the mixture was partitioned between ethyl acetate (300 ml) and water (300 ml), containing a small volume of brine, and the layers separated.
- the aqueous phase was further extracted with ethyl acetate (2x100 ml), and the combined organic solutions dried over magnesium sulphate and concentrated under reduced pressure, co-evaporating with tetrahydrofuran.
- the residual oil was purified by column chromatography on silica gel using an elution gradient of dichloromethane: ethyl acetate (80:20 to 50:50) to afford the title compound, as an oil that crystallised on standing (1.3g).
- Acetic acid (2.5-3.5eq) followed by dimethylamine (1.1-1.7eq) were added to a solution of the aldehyde from preparation 12 (1eq) in tetrahydrofuran (5mL per mmol) and the solution stirred for 15 minutes.
- Sodium triacetoxyborohydride (2- 2.3 eq.) was added, and the reaction stirred at room temperature for 17 hours.
- 2N hydrochloric acid was added, to give a pH of 1 , the mixture stirred for 15 minutes, then re-basified to pH 12 using 2N sodium hydroxide solution.
- the mixture was extracted with dichloromethane, the combined organic extracts dried (MgSO ) and evaporated under reduced pressure.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003263420A AU2003263420A1 (en) | 2002-09-17 | 2003-09-05 | COMBINATIONS OF ATORVASTATIN AND Alpha1, ADRENERGIC RECEPTOR ANTAGONISTS |
EP03797447A EP1542677A1 (en) | 2002-09-17 | 2003-09-05 | COMBINATIONS OF ATORVASTATIN AND a1, ADRENERGIC RECEPTOR ANTA GONISTS |
BR0314388-0A BR0314388A (en) | 2002-09-17 | 2003-09-05 | Combinations of atorvastatin and alpha1 adrenergic receptor antagonists |
CA002498894A CA2498894A1 (en) | 2002-09-17 | 2003-09-05 | Combinations of atorvastatin and .alpha.1, adrenergic receptor antagonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0221579.6 | 2002-09-17 | ||
GBGB0221579.6A GB0221579D0 (en) | 2002-09-17 | 2002-09-17 | Combinations of atorvastatin and, adrenergic receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004026300A1 true WO2004026300A1 (en) | 2004-04-01 |
Family
ID=9944250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2003/003940 WO2004026300A1 (en) | 2002-09-17 | 2003-09-05 | COMBINATIONS OF ATORVASTATIN AND α1, ADRENERGIC RECEPTOR ANTAGONISTS |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1542677A1 (en) |
CN (1) | CN1681492A (en) |
AU (1) | AU2003263420A1 (en) |
BR (1) | BR0314388A (en) |
CA (1) | CA2498894A1 (en) |
GB (1) | GB0221579D0 (en) |
PL (1) | PL374656A1 (en) |
TW (1) | TW200407123A (en) |
WO (1) | WO2004026300A1 (en) |
ZA (1) | ZA200502225B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100418529C (en) * | 2006-06-30 | 2008-09-17 | 南京美瑞制药有限公司 | Application of Nepider in preparing medicine to accelerate ejection of calculus for urinary system |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1238011B (en) * | 1989-12-13 | 1993-06-21 | Pulitzer Italiana | Pharmaceutical composition with an HMG - COA reductase inhibitor base, for treatment of benign prostatic hypertrophy (enlarged prostate gland) |
WO1998030560A1 (en) * | 1997-01-11 | 1998-07-16 | Pfizer Limited | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia |
WO1999011260A1 (en) * | 1997-08-29 | 1999-03-11 | Pfizer Inc. | Combination therapy comprising atorvastatin and an antihypertensive agent |
US20020004521A1 (en) * | 2000-01-07 | 2002-01-10 | Kenneth Weisman | Use of HMG-COA reductase inhibitors to prevent and treat BPH |
WO2003076427A1 (en) * | 2002-03-14 | 2003-09-18 | Pfizer Limited | Quinazoline compounds useful in therapy |
-
2002
- 2002-09-17 GB GBGB0221579.6A patent/GB0221579D0/en not_active Ceased
-
2003
- 2003-09-05 AU AU2003263420A patent/AU2003263420A1/en not_active Abandoned
- 2003-09-05 EP EP03797447A patent/EP1542677A1/en not_active Withdrawn
- 2003-09-05 PL PL03374656A patent/PL374656A1/en not_active Application Discontinuation
- 2003-09-05 CN CNA038217864A patent/CN1681492A/en active Pending
- 2003-09-05 BR BR0314388-0A patent/BR0314388A/en not_active Application Discontinuation
- 2003-09-05 WO PCT/IB2003/003940 patent/WO2004026300A1/en not_active Application Discontinuation
- 2003-09-05 CA CA002498894A patent/CA2498894A1/en not_active Abandoned
- 2003-09-16 TW TW092125472A patent/TW200407123A/en unknown
-
2005
- 2005-03-16 ZA ZA200502225A patent/ZA200502225B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1238011B (en) * | 1989-12-13 | 1993-06-21 | Pulitzer Italiana | Pharmaceutical composition with an HMG - COA reductase inhibitor base, for treatment of benign prostatic hypertrophy (enlarged prostate gland) |
WO1998030560A1 (en) * | 1997-01-11 | 1998-07-16 | Pfizer Limited | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia |
WO1999011260A1 (en) * | 1997-08-29 | 1999-03-11 | Pfizer Inc. | Combination therapy comprising atorvastatin and an antihypertensive agent |
US20020004521A1 (en) * | 2000-01-07 | 2002-01-10 | Kenneth Weisman | Use of HMG-COA reductase inhibitors to prevent and treat BPH |
WO2003076427A1 (en) * | 2002-03-14 | 2003-09-18 | Pfizer Limited | Quinazoline compounds useful in therapy |
Also Published As
Publication number | Publication date |
---|---|
BR0314388A (en) | 2005-07-19 |
CA2498894A1 (en) | 2004-04-01 |
EP1542677A1 (en) | 2005-06-22 |
AU2003263420A1 (en) | 2004-04-08 |
PL374656A1 (en) | 2005-10-31 |
CN1681492A (en) | 2005-10-12 |
ZA200502225B (en) | 2006-02-22 |
GB0221579D0 (en) | 2002-10-23 |
TW200407123A (en) | 2004-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI476192B (en) | Jak kinase modulating compounds and methods of use thereof | |
CN105683157B (en) | Sulfonamides as sodium channel modulators | |
EP1797877A1 (en) | Joint use of sulfonamide based compound with angiogenesis inhibitor | |
WO2020223229A1 (en) | Solid forms of a parp7 inhibitor | |
EA027689B1 (en) | Trifluormethyl-substituted ring-fused pyrimidines and use thereof | |
KR20150036367A (en) | N-substituted benzamides and methods of use thereof | |
WO2010139180A1 (en) | Naphthalene carboxamide derivatives as inhibitors of protein kinase and histone deacetylase, preparation methods and uses thereof | |
CN102458411A (en) | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors | |
TWI306095B (en) | Heterocyclylalkylamines as muscarinic receptor antagonists | |
WO2013013640A1 (en) | Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof | |
EA009744B1 (en) | Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions | |
WO2012030944A2 (en) | Quinoline and isoquinoline compounds and methods of use thereof | |
TW201016671A (en) | Novel imidazolidine compounds as androgen receptor modulators | |
KR20130102060A (en) | Quinazoline compounds and methods of use thereof | |
AU2018392985A1 (en) | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases | |
WO2021179959A1 (en) | Pharmaceutical composition comprising jak3/jak1/tbk1 inhibitor and methotrexate and use thereof | |
KR20180100651A (en) | Ovetiant for the treatment of chronic cough | |
CN104066324A (en) | Methods for treating gout flares | |
JP5731538B2 (en) | CRTH2 modulator | |
WO2004026300A1 (en) | COMBINATIONS OF ATORVASTATIN AND α1, ADRENERGIC RECEPTOR ANTAGONISTS | |
EP1380296A1 (en) | Hsp inductor | |
US20040132728A1 (en) | Combinations of atorvastatin and alpha1adrenergic receptor antagonists | |
MX2013010067A (en) | Derivatives of pyrazole-substituted amino-heteroaryl compounds. | |
AU2022245186A1 (en) | Treatment of hidradenitis suppurativa with orismilast | |
WO2015182625A1 (en) | Ras ACTIVITY INHIBITOR AND USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003263420 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 166871 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/A/2005/002044 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003797447 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 374656 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 538780 Country of ref document: NZ Ref document number: 2498894 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038217864 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500527 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/02225 Country of ref document: ZA Ref document number: 200502225 Country of ref document: ZA |
|
WWP | Wipo information: published in national office |
Ref document number: 2003797447 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003797447 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |